Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial.
Hassan M AbbasAl-Jumaili Ali AzeezKawthar F NassirMuhammed Waheeb Al-ObaidyAdnan Mohammed Al JubouriBasim Dhawi DakhilMohammed Mahir AbdulelahQutaiba Ahmed Al KhamesPublished in: International journal of clinical practice (2020)
This natural trial showed that the COVID-19 regimen containing both HCQ and azithromycin can be helpful to promote the recovery of most patients and reduced their signs and symptoms significantly. It also shows some manageable side effects mostly those related to heart rhythm. In the absence of FDA-approved medications to treat COVID-19, the repurposing of HCQ and azithromycin to control the disease signs and symptoms can be useful.
Keyphrases
- coronavirus disease
- sars cov
- clinical trial
- end stage renal disease
- ejection fraction
- study protocol
- newly diagnosed
- phase ii
- atrial fibrillation
- respiratory syndrome coronavirus
- peritoneal dialysis
- prognostic factors
- open label
- randomized controlled trial
- heart rate
- combination therapy
- double blind
- smoking cessation